{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T04:21:11Z","timestamp":1778127671294,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,6,7]],"date-time":"2011-06-07T00:00:00Z","timestamp":1307404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,6,7]],"date-time":"2011-06-07T00:00:00Z","timestamp":1307404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1038\/tpj.2011.23","type":"journal-article","created":{"date-parts":[[2011,6,7]],"date-time":"2011-06-07T10:07:10Z","timestamp":1307441230000},"page":"368-371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Gene expression in blood is associated with risperidone response in children with autism spectrum disorders"],"prefix":"10.1038","volume":"12","author":[{"given":"L","family":"Lit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F R","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Bertoglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Stamova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B P","family":"Ander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A D","family":"Sossong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R L","family":"Hendren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,6,7]]},"reference":[{"key":"BFtpj201123_CR1","first-page":"161","volume-title":"Autism Spectrum Disorders: A Research Review for Practitioners","author":"V des Portes","year":"2003","unstructured":"des Portes V, Hagerman RJ, Hendren RL . Pharmacotherapy. In: Ozonoff S, Rogers SJ, Hendren RL (eds). Autism Spectrum Disorders: A Research Review for Practitioners. American Psychiatric Association Publishing: Washington, DC, 2003, pp 161\u2013186."},{"key":"BFtpj201123_CR2","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/01.chi.0000196423.80717.32","volume":"45","author":"SK Williams","year":"2006","unstructured":"Williams SK, Scahill L, Vitiello B, Aman MG, Arnold LE, McDougle CJ et al. Risperidone and adaptive behavior in children with autism. J Am Acad Child Adolescent Psychiatry 2006; 45: 431\u2013439.","journal-title":"J Am Acad Child Adolescent Psychiatry"},{"key":"BFtpj201123_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/026988110101500108","volume":"15","author":"RA Bantick","year":"2001","unstructured":"Bantick RA, Deakin JF, Grasby PM . The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 2001; 15: 37\u201346.","journal-title":"J Psychopharmacol"},{"issue":"Suppl 4","key":"BFtpj201123_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/PL00014190","volume":"249","author":"J Ichikawa","year":"1999","unstructured":"Ichikawa J, Meltzer HY . Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur Arch Psychiatry Clin Neurosci 1999; 249 (Suppl 4): 90\u201398.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"Suppl 4","key":"BFtpj201123_CR5","first-page":"26","volume":"64","author":"AC Swann","year":"2003","unstructured":"Swann AC . Neuroreceptor mechanisms of aggression and its treatment. J Clin Psychiatry 2003; 64 (Suppl 4): 26\u201335.","journal-title":"J Clin Psychiatry"},{"key":"BFtpj201123_CR6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0022-3565(24)29589-6","volume":"297","author":"FI Tarazi","year":"2001","unstructured":"Tarazi FI, Zhang K, Baldessarini RJ . Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 2001; 297: 711\u2013717.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFtpj201123_CR7","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1176\/appi.ajp.162.6.1142","volume":"162","author":"CJ McDougle","year":"2005","unstructured":"McDougle CJ, Hollway J, Scahill L, Koenig K, Aman MG, McGough JJ et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 2005; 162: 1142\u20131148.","journal-title":"Am J Psychiatry"},{"key":"BFtpj201123_CR8","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJMoa013171","volume":"347","author":"JT McCracken","year":"2002","unstructured":"McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347: 314\u2013321.","journal-title":"N Engl J Med"},{"key":"BFtpj201123_CR9","doi-asserted-by":"publisher","first-page":"E634","DOI":"10.1542\/peds.2003-0264-F","volume":"114","author":"S Shea","year":"2004","unstructured":"Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004; 114: E634\u2013E641.","journal-title":"Pediatrics"},{"key":"BFtpj201123_CR10","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1089\/cap.2006.16.379","volume":"16","author":"GJ Pandina","year":"2006","unstructured":"Pandina GJ, Bossie CA, Zhu Y, Flanders S . The aberrant behavior checklist: use in clinical trials of pediatric autism. J Child Adolescent Psychopharmacol 2006; 16: 661\u2013662.","journal-title":"J Child Adolescent Psychopharmacol"},{"key":"BFtpj201123_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/hrp_8.2.45","volume":"8","author":"DJ Posey","year":"2000","unstructured":"Posey DJ, McDougle CJ . The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harv Rev Psychiatry 2000; 8: 45\u201363.","journal-title":"Harv Rev Psychiatry"},{"key":"BFtpj201123_CR12","first-page":"S463","volume":"15","author":"KP Su","year":"2005","unstructured":"Su KP, Wu PL, Pariante CM . A cross-over study on safety of lipid profiles associated with olanzapine and risperidone. Eur Neuropsychopharmacol 2005; 15: S463\u2013S464.","journal-title":"Eur Neuropsychopharmacol"},{"key":"BFtpj201123_CR13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2165\/00148581-200507050-00002","volume":"7","author":"A Danielyan","year":"2005","unstructured":"Danielyan A, Kowatch RA . Management options for bipolar disorder in children and adolescents. Paediatr Drugs 2005; 7: 277\u2013294.","journal-title":"Paediatr Drugs"},{"issue":"Suppl 4","key":"BFtpj201123_CR14","doi-asserted-by":"publisher","first-page":"S349","DOI":"10.1016\/S0924-9338(05)80190-7","volume":"20","author":"T Bottai","year":"2005","unstructured":"Bottai T, Quintin P, Perrin E . Antipsychotics and the risk of diabetes: a general data review. Eur Psychiatry 2005; 20 (Suppl 4): S349\u2013S357.","journal-title":"Eur Psychiatry"},{"key":"BFtpj201123_CR15","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.4088\/JCP.v66n0912","volume":"66","author":"JR McKee","year":"2005","unstructured":"McKee JR, Bodfish JW, Mahorney SL, Heeth WL, Ball MP . Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled. J Clin Psychiatry 2005; 66: 1161\u20131168.","journal-title":"J Clin Psychiatry"},{"key":"BFtpj201123_CR16","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1586\/14737175.5.6.713","volume":"5","author":"CA Erickson","year":"2005","unstructured":"Erickson CA, Stigler KA, Posey DJ, McDougle CJ . Risperidone in pervasive developmental disorders. Expert Rev Neurother 2005; 5: 713\u2013719.","journal-title":"Expert Rev Neurother"},{"key":"BFtpj201123_CR17","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1161\/STROKEAHA.110.588335","volume":"41","author":"B Stamova","year":"2010","unstructured":"Stamova B, Xu H, Jickling G, Bushnell C, Tian Y, Ander BP et al. Gene expression profiling of blood for the prediction of ischemic stroke. Stroke 2010; 41: 2171\u20132177.","journal-title":"Stroke"},{"key":"BFtpj201123_CR18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/0092-8674(93)90376-2","volume":"75","author":"T Sollner","year":"1993","unstructured":"Sollner T, Bennett MK, Whiteheart SW, Scheller RH, Rothman JE . A protein assembly-disassembly pathway in vitro that may correspond to sequential steps of synaptic vesicle docking, activation, and fusion. Cell 1993; 75: 409\u2013418.","journal-title":"Cell"},{"key":"BFtpj201123_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.neulet.2004.12.037","volume":"379","author":"DJ Muller","year":"2005","unstructured":"Muller DJ, Klempan TA, De Luca V, Sicard T, Volavka J, Czobor P et al. The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neurosci Lett 2005; 379: 81\u201389.","journal-title":"Neurosci Lett"},{"issue":"Part 6","key":"BFtpj201123_CR20","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1042\/bst0290722","volume":"29","author":"J Haase","year":"2001","unstructured":"Haase J, Killian AM, Magnani F, Williams C . Regulation of the serotonin transporter by interacting proteins. Biochem Soc Trans 2001; 29 (Part 6): 722\u2013728.","journal-title":"Biochem Soc Trans"},{"key":"BFtpj201123_CR21","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/DBP.0b013e3181ea50ed","volume":"31","author":"E Hanson","year":"2010","unstructured":"Hanson E, Nasir RH, Fong A, Lian A, Hundley R, Shen Y et al. Cognitive and behavioral characterization of 16p11.2 deletion syndrome. J Dev Behav Pediatr 2010; 31: 649\u2013657.","journal-title":"J Dev Behav Pediatr"},{"key":"BFtpj201123_CR22","doi-asserted-by":"publisher","first-page":"e727","DOI":"10.1542\/peds.2009-1684","volume":"125","author":"Y Shen","year":"2010","unstructured":"Shen Y, Dies KA, Holm IA, Bridgemohan C, Sobeih MM, Caronna EB et al. Clinical genetic testing for patients with autism spectrum disorders. Pediatrics 2010; 125: e727\u2013e735.","journal-title":"Pediatrics"},{"key":"BFtpj201123_CR23","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1093\/hmg\/ddq259","volume":"19","author":"E Vassos","year":"2010","unstructured":"Vassos E, Collier DA, Holden S, Patch C, Rujescu D, St Clair D et al. Penetrance for copy number variants associated with schizophrenia. Hum Mol Genet 2010; 19: 3477\u20133481.","journal-title":"Hum Mol Genet"},{"key":"BFtpj201123_CR24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0959-440X(96)80060-1","volume":"6","author":"KL Borden","year":"1996","unstructured":"Borden KL, Freemont PS . The RING finger domain: a recent example of a sequence-structure family. Curr Opin Struct Biol 1996; 6: 395\u2013401.","journal-title":"Curr Opin Struct Biol"},{"key":"BFtpj201123_CR25","first-page":"123","volume":"20","author":"FW Sunderman Jr","year":"1990","unstructured":"Sunderman Jr FW . The clinical biochemistry of 5\u2032-nucleotidase. Ann Clin Lab Sci 1990; 20: 123\u2013139.","journal-title":"Ann Clin Lab Sci"},{"key":"BFtpj201123_CR26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1089\/cap.2009.0022","volume":"20","author":"LE Arnold","year":"2010","unstructured":"Arnold LE, Farmer C, Kraemer HC, Davies M, Witwer A, Chuang S et al. Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability. J Child Adolesc Psychopharmacol 2010; 20: 83\u201393.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"BFtpj201123_CR27","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/tpj.2009.63","volume":"10","author":"CT Correia","year":"2010","unstructured":"Correia CT, Almeida JP, Santos PE, Sequeira AF, Marques CE, Miguel TS et al. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics J 2010; 10: 418\u2013430.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201123_CR28","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.biopsych.2009.08.030","volume":"67","author":"M Ikeda","year":"2010","unstructured":"Ikeda M, Tomita Y, Mouri A, Koga M, Okochi T, Yoshimura R et al. Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches. Biol Psychiatry 2010; 67: 263\u2013269.","journal-title":"Biol Psychiatry"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj201123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201123","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:42:09Z","timestamp":1741221729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,7]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["BFtpj201123"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2011.23","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,7]]},"assertion":[{"value":"16 November 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}